

ASX Release

23 September 2024

Director transition

Melbourne, Australia – Tryptamine Therapeutics Limited (**'Tryp'** or the **'Company'**) (**ASX: TYP**), a clinical-stage biotechnology company advises that Chief Business Officer and Executive Director, Mr Peter Molloy will transition from his role to a Non-Executive Director position effective 23 September 2024.

Mr Molloy has been a valuable member of the Company since September 2020 and has been influential in Tryp's growth trajectory to date. He provided extensive support in the Company's transition to the Australian Securities Exchange ('ASX') (refer ASX announcement: 29 May 2024) and upon the Company's successful transition to the ASX has made the decision to transition to a Non-Executive Director role.

As a Non-Executive Director, Mr Molloy will still take an active role in Tryp's ongoing clinical trial strategy and international investor engagement. The transition will result in cost savings for the Company and a streamlined executive management team, aligned with Tryp's ongoing focus on Australian operations.

Management commentary:

Non-Executive Chairman, Mr Mark Davies said: *"On behalf of the Board, I would like to thank Peter for his ongoing contribution to the Company in recent years and we look forward to continuing to leverage his expertise as a Non-Executive Director."*

"His transition aligns with the Company's strategy of utilising its Australian-based resources more aggressively to pursue clinical trial opportunities in the local market, which can be leveraged alongside R&D Tax Incentives. The Company continues to advance its strategy towards further trials utilising TRP-8803 (IV-infused psilocin) and we are confident a number of milestones will materialise in the coming months which will further solidify our position as a leading ASX-listed drug development company."

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803



(IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience. TRP-8803 is currently being evaluated in a Phase 1 Healthy Volunteer Study in Adelaide, Australia.

For more information, please visit www.tryptherapeutics.com.

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.